BridgeBio Pharma

Great to be at #ACMGMtg26 connecting with the community advancing care in #skeletaldysplasia. Inspired by the conversations and the progress to come ahead!

Children with #hypochondroplasia often wait years for a diagnosis. We brought together multidisciplinary experts to define clear, age-specific diagnostic opportunities and strengthen pathways for FGFR3 testing. We can close the gap between first signs and diagnosis. Explore our publication in @SpringerNature: bit.ly/409WFTD

The signs of LGMD2I/R9 may appear before movement stops. Symptom onset can range from childhood to early adulthood, contributing to potential diagnostic delays of 10 years or more. Learn more about #LGMD symptoms: knowlgmd.com/diagnosis-test…

For Gesna, her ATTR-CM diagnosis brought clarity to the symptoms that had impacted her family for generations. This #AmyloidosisAwarenessMonth, she's sharing her experience to encourage earlier conversations around family health history and greater awareness of hereditary ATTR (#ATTRv), especially in the African American community, where certain genetic variants may be more prevalent but remain underrecognized. By sharing her story, Gesna hopes to empower more people to ask questions, understand their risk, and take proactive steps toward earlier testing and care.

Proud to attend the Southern Society of Endocrinologists 2026 Annual Meeting in New Orleans. We were fortunate to engage with local attendees as well as endocrinologists from across the Southeast to discuss #ADH1 and the importance of genetic testing education. We value the opportunity to support continued education and collaboration within the endocrine community.

Additional positive interim Phase 3 FORTIFY data for oral BBP-418 in LGMD2I/R9 were presented today in a late-breaking oral session at #MDA2026. We are grateful to the individuals, families & investigators driving progress forward for the #LGMD community. Read more: bit.ly/4bhzbRD

We will participate in the @Barclays 28th Annual Global Healthcare Conference on March 11 at 12:30 pm EDT in Miami. RSVP to the webcast here: bit.ly/3OrBvxB $BBIO

Attending #ACMGMtg26? Visit our booth to experience Ethan’s story through an immersive VR perspective on living with achondroplasia. Education goes beyond data – it includes understanding lived experience and seeing the world through a new lens. Stop by to gain a different perspective.

We will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10 at 1:00 pm EDT in Miami. RSVP to our webcast: bit.ly/3MJttQk $BBIO

Heading to #BPIWest? Join us to learn how we’re strengthening safety in AAV9 gene therapy manufacturing. We’ll share a multi-step approach designed to carefully remove potential viral risks and how this framework could help streamline future programs. Learn more: bit.ly/4aYXnbi

March is #AmyloidosisAwarenessMonth. ❤️We’re grateful to the individuals living with this condition who have shared their stories and experiences with us. Listening to this community deepens understanding – and drives action. More to come throughout the month.

Attending @TheACMG? We’re looking forward to sharing four posters focused on our skeletal dysplasia programs onsite. #ACMG2026

Thrilled to share that additional interim Phase 3 FORTIFY data in LGMD2I/R9 will be presented in a late-breaking oral session at @MDAorg 2026. Plus, an oral presentation from Yale collaborators + four posters all advancing understanding of BBP-418 and LGMD2I/R9. We look forward to sharing more with the neuromuscular community. Learn more: bit.ly/4b3zaAL #MDA2026 #LGMD

Our team recently was on Capitol Hill for #RareDiseaseWeek, standing alongside people living with rare conditions, advocates, and policymakers. Nearly 30 million Americans live with a rare disease. Their voices deserve to be heard. This was a great opportunity to listen, learn, and advocate for policies that help shorten the path to diagnosis and accelerate access to treatment. 🦓

People living with rare diseases wait an average of 5 or more years for an accurate diagnosis. They may see up to 12 specialists searching for answers. Behind every number is a story of unanswered questions, uncertainty, and resilience. Sharing these stories builds awareness of the serious unmet need facing nearly 30 million people. In honor of #RareDiseaseDay, let’s stop and listen. Learn more from @RareDiseases: rarediseases.org

We will participate in the TD Cowen 46th Annual Healthcare Conference on Monday, March 2 at 3:50 pm EST in Boston. RSVP to our webcast: bit.ly/4r0gNSV $BBIO

As #AmericanHeartMonth wraps up, we’re reflecting on the power of community and the organizations working every day to support people impacted by heart disease. This month, our teams wore red to raise awareness and stand alongside the patients, families, and advocates moving #hearthealth forward. As we head into March and #AmyloidosisAwarenessMonth, we remain committed to advancing understanding, connection, and care. ❤️

Thank you @TreatNMD for convening the global neuromuscular community at #TREATNMD2026. We were proud to join the conversation, support distribution of the #LGMD Family Guide, and connect with clinicians, researchers, and advocates in Lisbon. Looking forward to continued collaboration beyond the meeting.

2025 marked a defining year for BridgeBio. As we close our first decade, we remain focused on translating bold science into transformative medicines for people living with genetic conditions. Full-year earnings: bit.ly/4sdzIel $BBIO